Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-4c: Apixaban for Post-Discharge COVID-19 Thromboprophylaxis
NCT04650087Phase 3Completed
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban in coronavirus disease 2019 (COVID-19). Started Feb 2021; status: completed.
02
Drugs
apixaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04650087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650087.